A comprehensive assessment of the safety of intravenous methamphetamine administration during treatment with selegiline

Pharmacology Biochemistry and Behavior

Volumn 82, Issue 4, 2005, Pages 704-711

  Newton, Thomas F ^a   De La Garza II, Richard ^a   Fong, Tim ^a   Chiang, Nora ^b   Holmes, Tyson H ^c   Bloch, Daniel A ^c   Anderson, Ann ^b   Elkashef, Ahmed ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

Addiction; Deprenyl; MAO B; Methamphetamine; Selegiline; Treatment

Indexed keywords

METHAMPHETAMINE; SELEGILINE;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DEPENDENCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; HEART RATE; HUMAN; LABORATORY TEST; MALE; MOOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SCREENING; SINGLE BLIND PROCEDURE;

ADULT; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METHAMPHETAMINE; MONOAMINE OXIDASE INHIBITORS; PLACEBOS; SELEGILINE; SINGLE-BLIND METHOD;

EID: 31844433206     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2005.11.012     Document Type: Article

References (23)

1. G. Bartzokis, M. Beckson, T. Newton, M. Mandelkern, J. Mintz, and J.A. Foster Selegiline effects on cocaine-induced changes in medial temporal lobe metabolism and subjective ratings of euphoria Neuropsychopharmacology 20 1999 582 590
2. F.C. Colpaert, C.J. Niemegeers, and P.A. Janssen Evidence that a preferred substrate for type B monoamine oxidase mediates stimulus properties of MAO inhibitors: a possible role for beta-phenylethylamine in the cocaine cue Pharmacol Biochem Behav 13 1980 513 517
3. C.E. Cook, A.R. Jeffcoat, J.M. Hill, D.E. Pugh, P.K. Patetta, and B.M. Sadler Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride Drug Metab Dispos 21 1993 717 723
4. G. Di Chiara, and A. Imperato Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats Proc Natl Acad Sci U S A 85 1988 5274 5278
5. T. Egashira, T. Yamamoto, and Y. Yamanaka Effects of d-methamphetamine on monkey brain monoamine oxidase, in vivo and in vitro Jpn J Pharmacol 45 1987 79 88
6. M. Gibaldi, and D. Perrier Pharmacokinetics 2 edn. 1982 Marcel Dekker
7. E.J. Houtsmuller, L.D. Notes, T. Newton, N. van Sluis, N. Chiang, and A. Elkashef Transdermal selegiline and intravenous cocaine: safety and interactions Psychopharmacology 172 2004 31 40 [Berl]
8. D.S. Kim, M.S. Szczypka, and R.D. Palmiter Dopamine-deficient mice are hypersensitive to dopamine receptor agonists J Neurosci 20 2000 4405 4413
9. W. Ling, and S. Shoptaw Integration of research in pharmacotherapy for addictive disease: where are we? Where are we going? J Addict Dis 16 1997 83 102
10. D.J. McCann, N.K. Mello, S.S. Negus, J. Bergman, M. Forster, and S. Schenk Selegiline as a potential cocaine treatment medication: behavioral evaluations in rhesus monkeys and comparisons with other MAO inhibitors in rodents Behav Pharmacol 10 1999 S59 S60
11. C. McGregor, M. Srisurapanont, J. Jittiwutikarn, S. Laobhripatr, T. Wongtan, and J.M. White The nature, time course and severity of methamphetamine withdrawal Addiction 100 2005 1320 1329
12. J.H. Mendelson, and N.K. Mello Management of cocaine abuse and dependence N Engl J Med 334 1996 965 972
13. J. Mendelson, R.T. Jones, R. Upton, and P. Jacob 3rd Methamphetamine and ethanol interactions in humans Clin Pharmacol Ther 57 1995 559 568
14. T.F. Newton, A. Kalechstein, M. Beckson, G. Bartzokis, T.P. Bridge, and W. Ling Effects of selegiline pretreatment on response to experimental cocaine administration Psychiatry Res 87 1999 101 106
15. T.F. Newton, A.D. Kalechstein, S. Duran, N. Vansluis, and W. Ling Methamphetamine abstinence syndrome: preliminary findings Am J Addict 13 2004 248 255
16. T.F. Newton, R. De La Garza II, A.D. Kalechstein, and L. Nestor Cocaine and methamphetamine produce different patterns of subjective and cardiovascular effects Pharmacol Biochem Behav 82 2005 90 97
17. T.F. Newton, J.D. Roache, R. De La Garza II, T. Fong, C.L. Wallace, S.-H. Li, A. Elkashef, H. Chiang, and R. Kahn Safety of intravenous methamphetamine administration during treatment with bupropion Psychopharmacology 182 2005 426 435
18. Newton TF, Roache JD, De La Garza II R, Fong T, Wallace CL, Li S-H, Elkashef A, Chiang H, Kahn R. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology, in press [Epub ahead of print, PMID:16319910].
19. W.K. Schiffer, M. Azmoodeh, M. Gerasimov, N.D. Volkow, J.S. Fowler, and S.L. Dewey Selegiline potentiates cocaine-induced increases in rodent nucleus accumbens dopamine Synapse 48 2003 35 38
20. N.D. Volkow, L. Chang, G.J. Wang, J.S. Fowler, D. Franceschi, and M. Sedler Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence J Neurosci 21 2001 9414 9418
21. J.M. Wilson, K.S. Kalasinsky, A.I. Levey, C. Bergeron, G. Reiber, and R.M. Anthony Striatal dopamine nerve terminal markers in human, chronic methamphetamine users Nat Med 2 1996 699 703
22. G.D. Winger, S. Yasar, S.S. Negus, and S.R. Goldberg Intravenous self-administration studies with l-deprenyl (selegiline) in monkeys Clin Pharmacol Ther 56 1994 774 780
23. S. Yasar, J.P. Goldberg, and S.R. Goldberg Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research J Neural Transm Suppl 48 1996 61 73